Intra-Cellular Therapies Inc (NASDAQ:ITCI) SVP Kimberly E. Vanover sold 9,564 shares of the business’s stock in a transaction dated Friday, January 4th. The stock was sold at an average price of $11.47, for a total transaction of $109,699.08. Following the completion of the sale, the senior vice president now owns 37,224 shares in the company, valued at $426,959.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

NASDAQ ITCI opened at $13.14 on Friday. The stock has a market cap of $718.01 million, a price-to-earnings ratio of -6.20 and a beta of 1.30. Intra-Cellular Therapies Inc has a 1 year low of $10.21 and a 1 year high of $25.82.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.85) by $0.09. Equities analysts expect that Intra-Cellular Therapies Inc will post -2.95 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Public Employees Retirement Association of Colorado grew its stake in Intra-Cellular Therapies by 127.8% during the 3rd quarter. Public Employees Retirement Association of Colorado now owns 5,687 shares of the biopharmaceutical company’s stock valued at $123,000 after acquiring an additional 3,190 shares in the last quarter. Cubist Systematic Strategies LLC grew its stake in Intra-Cellular Therapies by 53.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 9,641 shares of the biopharmaceutical company’s stock valued at $170,000 after acquiring an additional 3,339 shares in the last quarter. GSA Capital Partners LLP grew its stake in Intra-Cellular Therapies by 10.0% during the 2nd quarter. GSA Capital Partners LLP now owns 48,594 shares of the biopharmaceutical company’s stock valued at $859,000 after acquiring an additional 4,400 shares in the last quarter. Quantbot Technologies LP grew its stake in Intra-Cellular Therapies by 5,520.7% during the 3rd quarter. Quantbot Technologies LP now owns 4,609 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 4,527 shares in the last quarter. Finally, Schroder Investment Management Group grew its stake in Intra-Cellular Therapies by 0.6% during the 3rd quarter. Schroder Investment Management Group now owns 1,200,906 shares of the biopharmaceutical company’s stock valued at $26,060,000 after acquiring an additional 7,312 shares in the last quarter. Hedge funds and other institutional investors own 69.53% of the company’s stock.

Several equities research analysts have commented on the stock. Zacks Investment Research cut shares of Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research report on Thursday. Royal Bank of Canada boosted their price target on shares of Intra-Cellular Therapies from $35.00 to $37.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 12th. Canaccord Genuity set a $31.00 price target on shares of Intra-Cellular Therapies and gave the stock a “buy” rating in a research report on Wednesday, December 12th. Cantor Fitzgerald set a $32.00 price target on shares of Intra-Cellular Therapies and gave the stock a “buy” rating in a research report on Tuesday, December 11th. Finally, BidaskClub cut shares of Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research report on Tuesday, December 4th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $27.75.

ILLEGAL ACTIVITY WARNING: This report was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://theolympiareport.com/2019/01/11/insider-selling-intra-cellular-therapies-inc-itci-svp-sells-109699-08-in-stock.html.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.

Recommended Story: Are Wall Street analysts’ stock ratings worth following?

Insider Buying and Selling by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.